학술논문
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
Document Type
Article
Author
Source
In: Breast Cancer Research . (Breast Cancer Research, December 2023, 25(1))
Subject
Language
English
ISSN
1465542X
14655411
14655411